Taylor M. Ortiz

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Journal of Clinical Oncology · 2023 · 331 citations · Full text

Medicine, Oncology, Pharmacology +12

The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer

Stephanie Cardarella, Taylor M. Ortiz, Victoria A. Joshi et al. · Journal of Thoracic Oncology · 2012 · 110 citations

Medicine, Genetics, Oncology +14

G‐CSF is not necessary to maintain over 99% dose–intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10‐year analysis

Andrew M. Evens, Jeffrey Cilley, Taylor M. Ortiz et al. · British Journal of Haematology · 2007 · 85 citations

Medicine, Hematology, Oncology +15

CD34⁺ cell selection is required to assess <i>HOXA9</i> expression levels in patients with myelodysplastic syndrome

Stefan Heinrichs, Jason N. Berman, Taylor M. Ortiz et al. · British Journal of Haematology · 2005 · 13 citations

Medicine, Cell Biology, Hematology +11